Potential role of recombinant growth differentiation factor 11 in Alzheimer’s disease treatment

3Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease closely related to the accumulation of beta-amyloid (Aβ) plaques. Growth differentiation factor 11 (GDF11) is one of the proteins that play a role in the aggravation of AD. Decreased concentration of GDF11 disrupts regenerative nervous system, blood vessels, and various vital systems. Low levels of GDF11 with age can be overcome with recombinant GDF11 (rGDF11) to rejuvenate the regenerative effect. Based on research results, rGDF11 enhance the proliferation rate of neuronal precursor cells as well as angiogenesis. rGDF11 can replace lost levels of GDF11, overcome astrogliosis and activation of nerve cell microglia. Therapeutic effect of rGDF11 leads to an improved prognosis in AD patients by neurogenesis and angiogenesis. The prospects of rGDF11 in the treatment of AD have great potential for further research in the future.

Cite

CITATION STYLE

APA

de Liyis, B. G., Halim, W., & Widyadharma, I. P. E. (2022, December 1). Potential role of recombinant growth differentiation factor 11 in Alzheimer’s disease treatment. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1186/s41983-022-00487-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free